Immunoglobulins is named as an intervention in 5 current clinical trials in our Germany, France, UK, USA, Netherlands, Poland, Austria, Israel and Australia registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Assistance Publique - Hôpitaux de Paris (2). The most-studied condition is Thrombocytopenia, Neonatal Alloimmune. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Immunoglobulins. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma
2025-521571-30-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
| Lead sponsor | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| Janssen Research & Development, LLC | 1 |
| University of Ulm | 1 |
| Monash University | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
5 current trials in our Germany, France, UK, USA, Netherlands, Poland, Austria, Israel and Australia registers name Immunoglobulins as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 5 trials are recruiting: 2 with sites in Germany, 2 with sites in France, 1 with sites in UK, 1 with sites in USA, 1 with sites in Netherlands, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Israel and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Assistance Publique - Hôpitaux de Paris (2), Janssen Research & Development, LLC (1), University of Ulm (1) and Monash University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Immunoglobulins works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Immunoglobulins works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Immunoglobulins (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.